CRISPR/Cas mediated epigenome editing for cancer therapy

Area of Science:

• Oncology
• Epigenetics
• Gene Therapy

Background:

• Epigenetic alterations significantly influence gene expression and are implicated in carcinogenesis.
• Reversible epigenetic modifications present novel therapeutic targets for cancer treatment.
• Existing epigenetic therapies include DNA methyl transferase (DNMT) and histone deacetylase (HDAC) inhibitors.

Purpose of the Study:

• To review the role of epigenetics in cancer development.
• To explore the potential of CRISPR/Cas systems in epigenome editing for cancer therapy.
• To outline epigenetic therapeutic strategies using CRISPR/Cas.

Main Methods:

• Review of current literature on cancer epigenetics.
• Discussion of CRISPR/Cas technology for epigenome editing.
• Analysis of epigenetic editing's advantages over DNA gene editing.

Main Results:

• Epigenetic editing using CRISPR/Cas offers a precise method to alter epigenetic markers like DNA methylation and histone modifications.
• CRISPR/Cas-mediated epigenome editing avoids off-target DNA alterations, a key limitation of DNA gene editing.
• The reversibility of epigenetic changes combined with precise editing tools like CRISPR/Cas shows promise for novel cancer therapies.

Conclusions:

• Epigenetic modifications are crucial in cancer and offer therapeutic opportunities.
• CRISPR/Cas technology provides a powerful tool for epigenome editing in cancer.
• Epigenetic therapy using CRISPR/Cas represents a promising frontier in cancer treatment.